By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Pfizer's latest trial data on a new obesity drug raises questions about its tolerability, leading to a slight drop in the ...
Pfizer released trial data on a new obesity drug, raising concerns about tolerability. Despite a stock drop, the company aims ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
SAN FRANCISCO -- As more people are eligible to get vaccinated, reports of side effects after the second Pfizer and Moderna shots are surfacing. Dr. Robert Wachter, chief of medicine at UCSF says many ...
Investor's Business Daily on MSN
Pfizer dives; why Lilly's Zepbound still looks like the weight-loss heavyweight
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
As the race for the coronavirus vaccine continues, those in the trials for both Moderna and Pfizer are describing the side effects. "I'm Jennifer Haller and I'm the first person in the U.S. to trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results